We create pragmatic software solutions for Cell & Gene Therapy manufacturers
We excel in a sector where science meets health, health inspires technology – and together we improve human life.
Autolomous is enabling ATMP Manufacturers to bring autologous medicines to more patients. Using smart technology, we are driven to make this highly-specialised area of medicine deliverable, available and affordable.
WHAT IS PERSONALISED MEDICINE?
Personalised medicines begin with living cells from patients/donors which are modified outside of the body and infused back into the patient.
Current manufacturing processes are time-bound, labour intensive and require expensive GMP infrastructure to support complex supply chains. Current treatment costs range between £250,000 - £2,000,000 per patient.
The entire process must be rigorous and precise, therefore requires highly trained people to follow a carefully structured process.
Our bespoke software cuts huge amounts of administrative resource that supports the manufacturing process. Enabling manufacturing to be scaled up / out, while enhancing Quality Assurance, Data Integrity and security of the supply chain.
The intuitive laboratory-friendly interface pushes data securely to a distributed ledger, all data is immutable, precise and trackable. Each stakeholder in the value-chain is supported by a digital system, one that improves their efficiency and responsibilities.
The over-arching objective is to provide better access to cellular medicine.
We are developing innovative digital solutions to facilitate efficient manufacturing of personalised medicines
We want to inspire others to excel in the delivery of cellular medicines
Our ambition is to revolutionise data management within personalised medicine manufacturing and the accessibility to these life changing medicines.
"I'm proud to be a co-founder of Autolomous and part of providing affordable, bespoke software solutions to the common manufacturing roadblocks for cell & gene medicines. The AutoloMATE platform is already reducing costs and complexity in the academic, semi-automated CAR-T process in my own facility – fewer errors and less QA time. What's not to like?"
Prof. Mark Lowdell, Co-founder of Autolomous